TScan Therapeutics, Inc. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
TScan dosed the first patient in Phase 3 ALLOHA-2 trial (topline mid-2028) for TSC-101 treating heme malignancies post-transplant. Reported positive Cohort C Phase 1 data: 90% manufacturing success rate (17/19), 79% complete donor chimerism (11/14 patients), well-tolerated safety profile. Cash position $100.2M (excluding $5.0M restricted) funds operations into Q2 2027; net loss Q2 2026 was $30.4M; began term loan amortization Q4 2026 after missing non-covenant milestones.
Why this rating
Phase 3 initiation is clinically significant and de-risks development pathway. Positive manufacturing/efficacy data supports lead asset. However, $100M cash against $57M market cap provides ~9 months runway, creating near-term financing risk. Material relative to company size but execution-dependent.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.